Crop protection firm FMC's Q4 revenue misses estimates after Rynaxypyr price reduction

Reuters02-05 06:11

Crop protection firm FMC's Q4 revenue misses estimates after Rynaxypyr price reduction

Overview

Agricultural sciences firm's Q4 revenue missed analyst expectations, declining 12% yr/yr
Adjusted EPS for Q4 fell 33% yr/yr due to lower EBITDA and goodwill impairment
Company to explore strategic options, including potential sale, to enhance shareholder value

Outlook

FMC expects 2026 revenue between $3.60 bln and $3.80 bln, a 5% decline at midpoint
Adjusted EBITDA for 2026 projected at $670 mln to $730 mln, down 17%
FMC forecasts 2026 adjusted EPS between $1.63 and $1.89, a 41% decrease

Result Drivers

PRICE DECLINES - Revenue decline driven by 6% price reduction, primarily in Rynaxypyr, amid competitive pressures
NEW INGREDIENTS - Growth in new active ingredients like Isoflex and fluindapyr, despite overall revenue decline

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue	Miss	$1.08 bln	$1.15 bln (14 Analysts)

Press Release: ID:nPn4p3X6ra

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2609319577?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 06:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609319577","market":"nz","top_or_hot":-1,"title":"Crop protection firm FMC's Q4 revenue misses estimates after Rynaxypyr price reduction","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Crop protection firm FMC's Q4 revenue misses estimates after Rynaxypyr price reduction</title></head><body><p><span>Overview</span></p><ul><li><p>Agricultural sciences firm's Q4 revenue missed analyst expectations, declining 12% yr/yr</p></li><li><p>Adjusted EPS for Q4 fell 33% yr/yr due to lower EBITDA and goodwill impairment</p></li><li><p>Company to explore strategic options, including potential sale, to enhance shareholder value</p></li></ul><p><span>Outlook</span></p><ul><li><p>FMC expects 2026 revenue between $3.60 bln and $3.80 bln, a 5% decline at midpoint</p></li><li><p>Adjusted EBITDA for 2026 projected at $670 mln to $730 mln, down 17%</p></li><li><p>FMC forecasts 2026 adjusted EPS between $1.63 and $1.89, a 41% decrease</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>PRICE DECLINES - Revenue decline driven by 6% price reduction, primarily in Rynaxypyr, amid competitive pressures</p></li><li><p>NEW INGREDIENTS - Growth in new active ingredients like Isoflex and fluindapyr, despite overall revenue decline</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Miss</p></td><td><p>$1.08 bln</p></td><td><p>$1.15 bln (14 Analysts)</p></td></tr></tbody></table><p>Press Release: <span>ID:nPn4p3X6ra</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crop protection firm FMC's Q4 revenue misses estimates after Rynaxypyr price reduction</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrop protection firm FMC's Q4 revenue misses estimates after Rynaxypyr price reduction\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-05 06:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Crop protection firm FMC's Q4 revenue misses estimates after Rynaxypyr price reduction</title></head><body><p><span>Overview</span></p><ul><li><p>Agricultural sciences firm's Q4 revenue missed analyst expectations, declining 12% yr/yr</p></li><li><p>Adjusted EPS for Q4 fell 33% yr/yr due to lower EBITDA and goodwill impairment</p></li><li><p>Company to explore strategic options, including potential sale, to enhance shareholder value</p></li></ul><p><span>Outlook</span></p><ul><li><p>FMC expects 2026 revenue between $3.60 bln and $3.80 bln, a 5% decline at midpoint</p></li><li><p>Adjusted EBITDA for 2026 projected at $670 mln to $730 mln, down 17%</p></li><li><p>FMC forecasts 2026 adjusted EPS between $1.63 and $1.89, a 41% decrease</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>PRICE DECLINES - Revenue decline driven by 6% price reduction, primarily in Rynaxypyr, amid competitive pressures</p></li><li><p>NEW INGREDIENTS - Growth in new active ingredients like Isoflex and fluindapyr, despite overall revenue decline</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Miss</p></td><td><p>$1.08 bln</p></td><td><p>$1.15 bln (14 Analysts)</p></td></tr></tbody></table><p>Press Release: <span>ID:nPn4p3X6ra</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4545","symbol_name":"锂电池","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nL1N3Z01IV:1","article_id":"2609319577","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609319577","pubTimestamp":1770243080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Crop protection firm FMC's Q4 revenue misses estimates after Rynaxypyr price reductionOverviewAgricultural sciences firm's Q4 revenue missed analyst expectations, declining 12% yr/yrAdjusted EPS for Q","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4545":"锂电池","LU0385154629.USD":"贝莱德营养科学基金A2","BK4588":"碎股","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","BK4093":"化肥与农用药剂","BK4585":"ETF&股票定投概念","FMC":"FMC Corp."},"translate_title":"Rynaxypyr降价后，作物保护公司FMC第四季度收入未达预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FMC":0.9},"content_text":"Crop protection firm FMC's Q4 revenue misses estimates after Rynaxypyr price reductionOverviewAgricultural sciences firm's Q4 revenue missed analyst expectations, declining 12% yr/yrAdjusted EPS for Q4 fell 33% yr/yr due to lower EBITDA and goodwill impairmentCompany to explore strategic options, including potential sale, to enhance shareholder valueOutlookFMC expects 2026 revenue between $3.60 bln and $3.80 bln, a 5% decline at midpointAdjusted EBITDA for 2026 projected at $670 mln to $730 mln, down 17%FMC forecasts 2026 adjusted EPS between $1.63 and $1.89, a 41% decreaseResult DriversPRICE DECLINES - Revenue decline driven by 6% price reduction, primarily in Rynaxypyr, amid competitive pressuresNEW INGREDIENTS - Growth in new active ingredients like Isoflex and fluindapyr, despite overall revenue declineKey DetailsMetricBeat/MissActualConsensus EstimateQ4 RevenueMiss$1.08 bln$1.15 bln (14 Analysts)Press Release: ID:nPn4p3X6raFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2609319577","isCrawlerRequest":true}